Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Azad

Showing results (131-140 of 199) with videos related to

Pageof 20
Sort By:
Targeted Oncology|May 13, 2014
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumabJosep Tabernero, Sant P Chawla, Hedy Kindler, et al.
Journal of the American Chemical Society|December 13, 2022
Thermally Controlled Exciplex Fluorescence in a Dynamic Homo[2]catenaneAmine Garci, Arthur H G David, Laura Le Bras, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 24, 2015
Survival in sensitized lung transplant recipients with perioperative desensitizationK J Tinckam, S Keshavjee, C Chaparro, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The American Surgeon|May 9, 2025
Sustained Organ Preservation in Patients With Rectal Cancer After Sequential Short-Course Radiation Therapy and ChemotherapyI-Chia Liu, Susan Gearhart, Chen Hu, et al.
Cancer|December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trialsFen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract CancerAmanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
International Journal of Cancer|February 5, 2024
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patientsValerie Lee, Rose Parkinson, Marianna Zahurak, et al.
Pageof 20

Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
Targeted Oncology|May 13, 2014
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumabJosep Tabernero, Sant P Chawla, Hedy Kindler, et al.
Journal of the American Chemical Society|December 13, 2022
Thermally Controlled Exciplex Fluorescence in a Dynamic Homo[2]catenaneAmine Garci, Arthur H G David, Laura Le Bras, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 24, 2015
Survival in sensitized lung transplant recipients with perioperative desensitizationK J Tinckam, S Keshavjee, C Chaparro, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The American Surgeon|May 9, 2025
Sustained Organ Preservation in Patients With Rectal Cancer After Sequential Short-Course Radiation Therapy and ChemotherapyI-Chia Liu, Susan Gearhart, Chen Hu, et al.
Cancer|December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trialsFen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract CancerAmanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
International Journal of Cancer|February 5, 2024
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patientsValerie Lee, Rose Parkinson, Marianna Zahurak, et al.
Pageof 20